David Spigel, MD, director of Lung Cancer Research at the Sarah Cannon Research Institute, discusses results from a phase III study exploring eribulin for the treatment of patients with non-small cell lung cancer.
The two arms on this trial were similar — about 40% of patients on both arms were Asian. Most patients received gemcitabine or docetaxel.
The primary endpoint on this trial, overall survival, was not improved. Progression-free survival and response rates were similar between the two arms.
<<< View more from the 2014 Multidisciplinary Symposium in Thoracic Oncology